Volume 14 Issue 2, February 2017

Volume 14 Issue 2

Cover image supplied by Carolina Tropini, Sonnenburg Group, Stanford University, USA, who is funded by a James S. McDonnell fellowship. Fluorescent in situ hybridization of mouse colon colonized with gnotobiotic microbiota. Tissue was stained by DAPI and the mucus labelled with UEA-1 (Ulex europaeus agglutinin I), bacteria were labelled with fluorescent DNA probes.

Research Highlights

Year in Review

Reviews

  • Review Article |

    Here, the authors comprehensively explore evidence that maternal obesity and/or obesogenic diet, mediated by factors such as altered maternal metabolism, microbiota colonization, macrophage programming and epigenetic changes, can programme NAFLD risk and disease progression in offspring. Current and potential clinical interventions are also discussed.

    • Stephanie R. Wesolowski
    • , Karim C. El Kasmi
    • , Karen R. Jonscher
    •  & Jacob E. Friedman
  • Review Article |

    Effective diagnostic imaging can improve prognosis for patients with pancreatic diseases such as pancreatitis, pancreatic cancer and diabetes mellitus, which benefit from early treatment. Here, Kelly and colleagues review current and future technologies for imaging pancreatic disease, and discuss the development of new contrast agents and molecular imaging targets.

    • Julien Dimastromatteo
    • , Teresa Brentnall
    •  & Kimberly A. Kelly
  • Review Article |

    Obesity affects 15–40% of patients with IBD. Here, Singh and colleagues discuss the evidence linking obesity to IBD pathogenesis, the effect of obesity on disease outcomes and treatment response, and obesity-related issues in abdominal imaging and IBD surgery.

    • Siddharth Singh
    • , Parambir S. Dulai
    • , Amir Zarrinpar
    • , Sonia Ramamoorthy
    •  & William J. Sandborn
  • Review Article |

    Chronic HCV infection is a global health problem. In this Review, the authors describe the global burden of hepatitis C and HCV-related disease, including hepatocellular carcinoma, cirrhosis and extrahepatic manifestations. How the new direct-acting antiviral agents might influence disease burden is also discussed.

    • Aaron P. Thrift
    • , Hashem B. El-Serag
    •  & Fasiha Kanwal